Table 3.
Metabolic pathway analysis: pathway discriminating early and advanced ALS patients. For each pathway is reported p-value, FDR value.
| Pathway | Software | p-Value | FDR. |
|---|---|---|---|
| Ammonia Recycling | Metaboanalyst | 7.27 × 10−10 | 0.000538 |
| Mitochondrial Beta-Oxidation of Long-Chain Saturated Fatty Acids | Metaboanalyst | 0.0125 | 0.056 |
| Carnitine Synthesis | Metaboanalyst | 0.0125 | 0.0564 |
| Beta Oxidation of Very Long Chain Fatty Acids | Metaboanalyst | 0.015 | 0.0564 |
| Oxidation of Branched Chain Fatty Acids | Metaboanalyst | 0.015 | 0.0564 |
| Amine ligand-binding receptors | Reactome | 1.30 × 10−3 | 1.39 × 10−6 |
| Serotonin receptors | Reactome | 1.10 × 10−5 | 5.89 × 10−6 |
| Defective SLC6A19 causes Hartnup disorder (HND) | Reactome | 3.80 × 10−10 | 0.008 |
| Na−/Cl− dependent neurotransmitter transporters | Reactome | 5.13 × 10−10 | 0.009 |
| Cytosolic tRNA aminoacylation | Reactome | 8.64 × 10−9 | 0.011 |
| Class A/1 (Rhodopsin-like receptors) | Reactome | 9.88 × 10−10 | 0.011 |
| Adrenoceptors | Reactome | 1.26 × 10−12 | 0.013 |
| Muscarinic acetylcholine receptors | Reactome | 1.47 × 10−11 | 0.014 |
| GPCR ligand binding | Reactome | 5.59 × 10−11 | 0.048 |
| Chemokine receptors bind chemokines | Reactome | 5.88 × 10−11 | 0.048 |
| Adrenaline signaling through Alpha-2 adrenergic receptor | Reactome | 0.001 | 0.105 |
| Adenylate cyclase inhibitory pathway | Reactome | 0.007 | 0.492 |